Distinct Roles of HES1 in Normal Stem Cells and Tumor Stem-like Cells of the Intestine

• Published in: Cancer research (Chicago, Ill.) Vol. 77; no. 13; pp. 3442 - 3454
• Main Authors: Goto, Norihiro, Ueo, Taro, Fukuda, Akihisa, Kawada, Kenji, Sakai, Yoshiharu, Miyoshi, Hiroyuki, Taketo, Makoto Mark, Chiba, Tsutomu, Seno, Hiroshi
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research, Inc 01.07.2017
• Subjects: Animals; Apoptosis; Cancer; Cell Line, Tumor; Cell self-renewal; Cell Transformation, Neoplastic; Clonal deletion; Feasibility studies; Homeostasis; Humans; Intestinal Neoplasms - metabolism; Intestinal Neoplasms - pathology; Intestine; Intestines - metabolism; Intestines - pathology; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells - metabolism; Neoplastic Stem Cells - pathology; Rodents; Stem cell transplantation; Stem cells; Transcription Factor HES-1 - genetics; Transcription Factor HES-1 - metabolism; Transcription factors; Tumors; β-Catenin
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.can-16-3192

Cancer stem cells (CSC) have attracted attention as therapeutic targets; however, CSC-targeting therapy may disrupt normal tissue homeostasis because many CSC molecules are also expressed by normal stem cells (NSC). Here, we demonstrate that NSC-specific and CSC-specific roles of the stem cell transcription factor Hes1 in the intestine enable the feasibility of a specific cancer therapy. Hes1 expression was upregulated in NSCs and intestinal tumors. Lineage-tracing experiments in adult mouse intestine revealed that Hes1 deletion in Lgr5 or Bmi1 NSCs resulted in loss of self-renewal but did not perturb homeostasis. Furthermore, in Lgr5 NSC, deletion of Hes1 and β-catenin stabilization limited tumor formation and prolonged host survival. Notably, in Lgr5 or Dclk1 tumor stem cells derived from established intestinal tumors, Hes1 deletion triggered immediate apoptosis, reducing tumor burden. Our results show how Hes1 plays different roles in NSCs and CSCs, in which Hes1 disruption leads to tumor regression without perturbing normal stem cell homeostasis, preclinically validating Hes1 as a cancer therapeutic target. .